Evaluation of effects of Ra-223 chloride therapy for bone metastasis of prostate cancer by quantitative bone SPECT/CT
Not Applicable
- Conditions
- Bone metastasis of castration resistant prostate cancer
- Registration Number
- JPRN-UMIN000024201
- Lead Sponsor
- Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
? A patient with bone metastasis of castration resistant prostate cancer
? A patient without known massive metastatic lesion except bone metastasis
? A patient who is done or planned a quantitative bone SPECT/CT within 30 days before the initial administration of Ra-233 therapy
? A patient who consents to this study on the document form
Exclusion Criteria
? A patient with worse bone marrow dysfunction more than WHO grade III
? A patient with any massive metastatic lesion except bone, such as brain, lung or liver
? A patient who received radiation therapy or surgical therapy within 30 days, or who plans either therapy
? A patient who deny the prosecution of this study in the middle of the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method